November 2, 2017
Authored and Edited by Marianne S. Terrot, Ph.D.; Kevin D. Rodkey; Elizabeth D. Ferrill
In Merck Sharp & Dohme Corp. v. Hospira, Inc., No. 2017-1115 (Fed. Cir. Oct. 26, 2017), a divided Federal Circuit panel affirmed the district court’s finding that a claimed process for making a chemical compound was obvious. Merck sued Hospira alleging infringement of U.S. Patent Nos. 6,486,150 and 5,952,323 after Hospira filed an ANDA for a generic version of Merck’s Invanz® product. After a bench trial the district court found the ’323 patent infringed and not invalid and the ’150 patent invalid as obvious because the claimed steps could have been discovered by routine experimentation. Merck appealed the invalidity finding.
On appeal, the panel majority affirmed, holding that the claimed process recited “experimental details that one of ordinary skill would have utilized via routine experimentation, armed with the principles disclosed in the prior art.” Specifically, the majority found that the claimed “solution” was “nothing more than conventional manufacturing steps that implement principles disclosed in the prior art.” Although the majority faulted the district court for not considering Merck’s commercial success evidence because Merck owned another patent covering the ’150 patent’s product, it found no clear error in the ultimate obviousness determination. The majority agreed that Merck’s evidence of commercial success and copying did not overcome the competing evidence of obviousness.
Judge Newman dissented, arguing the majority and district court improperly “converted three of the four Graham factors into a self-standing ‘prima facie’ case, whereby the objective considerations must achieve rebuttal weight.”
Copyright © 2017 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.